v3.26.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2025
Jul. 31, 2025
Titan Pharmaceuticals Inc [Member]    
Schedule of Deferred Tax Assets

(in thousands of U.S. dollars)      
  

As of

December 31,

 
(in thousands of U.S. dollars)  2025   2024 
Deferred tax assets:          
Net operating loss carryforwards  $45,516   $49,611 
Research credit carryforwards   8,731    9,214 
Other, net   895    1,655 
Total deferred tax assets   55,142    60,480 
Deferred tax liabilities:          
Other, net   -    - 
Total deferred tax liabilities   -    - 
Valuation allowance   (55,142)   (60,480)
Net deferred tax assets  $-   $- 
 
Schedule of Reconciliation Actual Benefit of (provision For) Income Taxes

The provision for income taxes is zero due to operating losses. The effective tax rate of our provision (benefit) for income taxes differs from the federal statutory rate as follows:

   

(in thousands of U.S. dollars)      
   For the
Years Ended
December 31,
 
(in thousands of U.S. dollars)  2025   2024 
Computed at 21%  $(522)  $(980)
State taxes   -    (436)
Change in valuation allowance   (5,116)   (4,547)
Other   171    1 
Stock based compensation   273    74 
Research and development credits   (161)   (185)
Tax attributes expirations   5,355    6,082 
Impact of IRC 162m   -    (8)
Total  $-   $1 
 
TALENTEC SDN. BHD. [Member]    
Schedule of Deferred Tax Assets  

Deferred tax assets have not been recognized in respect of the following items:

 

       
   For the years ended July 31, 
   2024   2025 
Deferred tax assets:          
Net operating loss carry-forwards  $189,010   $146,561 
Total deferred tax assets   189,010    146,561 
Less: Valuation allowance   (189,010)   (146,561)
Total deferred tax assets, net  $-   $- 
Schedule of Reconciliation Actual Benefit of (provision For) Income Taxes  

A reconciliation between the Group’s actual provision for income taxes at the Malaysian statutory rate is as follows:

 

       
   For the years ended July 31, 
   2024   2025 
Income before income tax expense  $153,227   $209,911 
Income tax expense at the statutory rate of 17%   26,049    35,685 
Tax effect of non-deductible expense   124    3,341 
Tax effect of other temporary differences   1,094    (3,132)
Unrecognized deferred tax assets   (25,871)   8,575 
Utilize prior year tax losses which not recorded deferred tax assets   (1,396)   (44,469)
Income taxes expense  $-   $- 
Schedule of Components of Income Before Income Taxes  

The components of loss/income before income taxes were comprised of the following:

 

       
   For the years ended July 31, 
   2024   2025 
Tax jurisdictions from:          
-Malaysia  $145,017   $260,353 
-Singapore   8,210    (50,442)
Income before income taxes  $153,227   $209,911 
Schedule of Provision for Income Taxes  

The provision for income taxes consisted of the following:

 

       
   For the years ended July 31, 
   2024   2025 
Current:          
-Malaysia  $-   $- 
-Singapore   -    - 
           
Deferred:          
-Malaysia   -    - 
-Singapore   -    - 
Income tax expense  $-   $- 
Schedule of Changes in Valuation Allowance  

Changes in valuation allowance are as follows:

  

       
   For the years ended July 31, 
   2024   2025 
Balance at the beginning of the year  $242,146   $189,010 
Additions   (1,396)   8,575 
Utilization   (47,446)   (59,233)
Foreign exchange effect   (4,294)   8,208 
Balance at the end of the year  $189,010   $146,561